Marcus, F. BOEHM,Esther MARTINBOROUGH,Manisha MOORJANI,Junko TAMIYA,Liming HUANG,Adam, R. YEAGER,Enugurthi BRAHMACHARY,Thomas FOWLER,Andrew NOVAK,Premji MEGHANI,Michael KNAGGS
申请号：
HK16110429.2
公开号：
HK1222177A
申请日:
2016.09.01
申请国别(地区):
HK
年份:
2017
代理人:
摘要：
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where &ldquo&rdquo represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
